Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees

J Psychiatr Res. 1998 Sep-Oct;32(5):255-9. doi: 10.1016/S0022-3956(98)00004-1.


Concordance to antidepressant response in members of the same family is a common observation in clinical practice. However, few published data support this view; moreover families with affected members responder to the same antidepressant have been poorly studied. We have analyzed 45 pairs consisting of one mood disorder fluvoxamine double-responder proband and one first-degree relative with known outcome to fluvoxamine treatment. Among 45 pairs 30 (67%) were concordant for good response to fluvoxamine. In family pedigrees of concordant pairs we found a significantly higher distribution of bipolar forms in secondary cases than in families of non concordant pairs (14.9% vs 3.9% P = 0.039) suggesting that concordance to antidepressant therapy could select families with higher genetic loading.

MeSH terms

  • Adult
  • Antidepressive Agents, Second-Generation / adverse effects
  • Antidepressive Agents, Second-Generation / therapeutic use*
  • Bipolar Disorder / drug therapy*
  • Bipolar Disorder / genetics*
  • Depressive Disorder, Major / drug therapy*
  • Depressive Disorder, Major / genetics*
  • Female
  • Fluvoxamine / adverse effects
  • Fluvoxamine / therapeutic use*
  • Genetic Predisposition to Disease / genetics*
  • Humans
  • Male
  • Middle Aged
  • Pedigree
  • Treatment Outcome


  • Antidepressive Agents, Second-Generation
  • Fluvoxamine